FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/07/2023
Back to search
Official data from USPTO
NORTHWAY GENE THERAPY CENTER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
02/07/2023
Trademark type
Combined
Nice classes
5, 42
Filing date
11/18/2020
Registration date
09/27/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/27/2022
Last transaction
09/27/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
16
Owner location
LT
Examiner
CUELLO, GIDETTE
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "NORTHWAY GENE THERAPY CENTER," with the "O" in NORTHWAY being represented by the design of a DNA Helix in dark blue and orange, the rest of the wording "NORTHWAY" in dark blue, and the wording "GENE THERAPY CENTER" below in orange. The color white represents background and/or transparent areas and is not claimed as a feature of the mark.
Holders and representatives
Holders
UAB "Northway turto valdymas"
Representatives
JOHN ZACCARIA NOTARO MICHALOS & ZACCARIA PC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsfor the treatment of oncologicalcardiovascularrespiratoryinflammatoryautoimmune and degenerative diseases and disordersrheumatoid arthritismultiple sclerosisallergies and COVID-19; drugs for medical purposespharmaceutical preparations for the treatment of oncologicalcardiovascularrespiratoryinflammatoryautoimmune and degenerative diseases and disordersrheumatoid arthritismultiple sclerosisallergies and COVID-19; biological preparations for medical purposesfor the treatment of oncologicalcardiovascularrespiratoryinflammatoryautoimmune and degenerative diseases and disordersrheumatoid arthritismultiple sclerosisallergies and COVID-19; biological tissue cultures for medical purposesfor the treatment of oncologicalcardiovascularrespiratoryinflammatoryautoimmune and degenerative diseases and disordersrheumatoid arthritismultiple sclerosisallergies and COVID-19; albuminous preparations for medical purposesalbumin dietary supplements; chemical preparations for medical purposesfor the treatment of oncologicalcardiovascularrespiratoryinflammatoryautoimmune and degenerative diseases and disordersrheumatoid arthritismultiple sclerosisallergies and COVID-19
Class 42
Scientific and technological services and research and design relating theretoresearch and design in the field of products and processes development of biotechnology products and processes; bacteriological research; biological research; chemistry services in the nature of product development and quality control of biotechnology products; chemical research; conducting clinical trials for others; scientific research; medical research; scientific laboratory services; technical research in the field of pharmaceutical studies; technological consultancy in the field of development of manufacturing processes for biotechnology products
Publications
History of USPTO decisions and trademark events.
47 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/13/2023
FIMP
FINAL DISPOSITION PROCESSED
01/13/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/27/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/27/2022
TMBN
TTAB RELEASE CASE TO TRADEMARKS
08/24/2022
OP.T
OPPOSITION TERMINATED NO. 999999
08/24/2022
OP.D
OPPOSITION DISMISSED NO. 999999
08/24/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/27/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/06/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/01/2022
RFNT
REFUSAL PROCESSED BY IB
02/06/2022
OP.I
OPPOSITION INSTITUTED NO. 999999
01/20/2022
OPNS
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
01/12/2022
OPNC
OPPOSITION NOTICE (IB REFUSAL) CREATED
01/12/2022
OPPF
OPPOSITION PAPERS RECEIVED AT TTAB
01/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
12/19/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/14/2021
PUBO
PUBLISHED FOR OPPOSITION
12/14/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/26/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/24/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/24/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/08/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
11/08/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/08/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
11/08/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/22/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/22/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/22/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/22/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/22/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/22/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/22/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/22/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/22/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/16/2021
RFNT
REFUSAL PROCESSED BY IB
05/30/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/13/2021
RFRR
REFUSAL PROCESSED BY MPU
05/13/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/11/2021
CNRT
NON-FINAL ACTION WRITTEN
05/10/2021
DOCK
ASSIGNED TO EXAMINER
04/30/2021
MAFR
APPLICATION FILING RECEIPT MAILED
01/08/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/04/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/31/2020
Continuous trademark protection
Get notified about every new filing that threatens NORTHWAY GENE THERAPY CENTER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.